Hapoalim rated Outperform Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) on 06/25/2009, when the stock price was $27.59. Since then, Auxilium Pharmaceuticals, Inc. has gained 32.19% as of 01/29/2015's recent price of $36.47.
If you would have followed this Hapoalim's recommendation on AUXL, you would have gained 32.18% of your investment in 2044 days.

Auxilium Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops and markets products for urology and sexual health. Auxilium markets Testim 1%, a topical testosterone gel, for the treatment of hypogonadism. Auxilium is developing additional Testim line extensions, as well as other products for urology and sexual health, including an enzyme in Phase II for the treatment of Peyronie's Disease that may also prove useful for the treatment of Dupuytren's Disease.

Hapoalim Securities redistributes fundamental research on Israeli growth companies written by professional analysts employed by our affiliate, Bank Hapoalim B.M. The research product has an emphasis and strength in diversified sectors, including technology, communications and pharmaceutical companies. The strength of Hapoalim's relationships with these companies allows us to provide clients with access to the managements of the companies as necessary.

Marked as spam